XTX Topco Ltd Has $29,000 Holdings in Immuneering Co. (NASDAQ:IMRX)

XTX Topco Ltd trimmed its stake in Immuneering Co. (NASDAQ:IMRX) by 65.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,779 shares of the company’s stock after selling 22,380 shares during the period. XTX Topco Ltd’s holdings in Immuneering were worth $29,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. HighTower Advisors LLC lifted its stake in shares of Immuneering by 21.4% in the third quarter. HighTower Advisors LLC now owns 53,360 shares of the company’s stock valued at $132,000 after buying an additional 9,400 shares during the period. Corsair Capital Management L.P. acquired a new stake in shares of Immuneering during the 3rd quarter worth approximately $25,000. Vontobel Holding Ltd. bought a new stake in shares of Immuneering during the third quarter valued at approximately $25,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Immuneering during the second quarter valued at approximately $44,000. Finally, Tidemark LLC bought a new position in Immuneering in the third quarter worth $129,000. Institutional investors own 67.65% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on IMRX shares. Morgan Stanley lowered shares of Immuneering from an “equal weight” rating to an “underweight” rating in a report on Friday, December 13th. Needham & Company LLC reissued a “buy” rating and issued a $15.00 price target on shares of Immuneering in a research report on Thursday, November 14th. Finally, Chardan Capital reiterated a “buy” rating and issued a $13.00 price objective on shares of Immuneering in a research note on Wednesday, November 20th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Immuneering has a consensus rating of “Hold” and a consensus price target of $12.80.

Immuneering Stock Up 8.7 %

NASDAQ:IMRX opened at $2.00 on Monday. The firm has a market cap of $62.10 million, a PE ratio of -1.02 and a beta of -0.33. Immuneering Co. has a 12 month low of $1.00 and a 12 month high of $7.92. The company’s 50-day moving average price is $2.01 and its two-hundred day moving average price is $1.70.

Immuneering Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.